The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.
In a study published today in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, investigators used nationwide prescription data to determine that the current annual U.S. sales of new antibiotics to treat carbapenem-resistant Enterobacteriaceae (CRE), one of the world’s most insidious drug-resistant bacteria, is about $101 million annually — significantly short of the $1 billion believed to be necessary to assure the financial viability of a new antibiotic. Even if new anti-CRE agents were used as widely as possible to treat CRE infections, the projected market size is only $289 million.
“New drugs against CRE address a major, previously unmet medical need and are critical to save lives. If the market can’t support them, then that is a chilling commentary on the future of antibiotic development,” said lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases. “Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries.”
CRE infections are estimated to cause 1.5 to 4.5 million hospitalizations worldwide each year. The Centers for Disease Control and Prevention has classified CRE as urgent threat pathogens and calls them the “nightmare bacteria.” The World Health Organization and Infectious Disease Society of America have designated CRE as highest priority pathogens for development of new antibiotics.
Since 2015, five antibiotics against CRE have gained U.S. Food and Drug Administration approval and trials have so far shown three of them to be more effective and less toxic than the previous first-line antibiotics. One of the developers of the new anti-CRE drugs — the biopharmaceutical company Achaogen — declared bankruptcy in April because of its steep losses.
After reporting earlier this year that new CRE antibiotics are being prescribed in only about a quarter of infections that warrant them, Clancy and senior author M. Hong Nguyen, M.D., Pitt professor of medicine and director of UPMC’s Antimicrobial Management Program, investigated the market needed to make antibiotic development sustainable. They found a shortfall in revenue potential, evidenced by the financial difficulties faced by drug companies that created the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” said Nguyen. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Clancy and Nguyen propose a combination of “push” and “pull” incentives to encourage sustainable antibiotic development, starting with approval of the bilateral DISARM Act, which currently is under consideration in Congress. DISARM would assure full Centers for Medicare and Medicaid Services reimbursement for use of new antibiotics against resistant infections in hospitalized patients, rather than subsuming antibiotic costs into the discounted bundled payment hospitals receive. This would remove the disincentive hospitals face in using more effective but more expensive new agents rather than cheaper, older agents.
There also needs to be a cultural and behavioral change among hospitals and clinicians to encourage faster adoption and appropriate use of new antibiotics, the researchers said. Infectious disease physicians and pharmacists need to take responsibility for educating the wider clinical community about the importance of quickly updating and following guidelines on the best possible antibiotics to be using for their patients.
The Latest on: The future of antibiotics
via Google News
The Latest on: The future of antibiotics
- Europe Oral Antibiotics Market Future Scope, Opportunities with Strategic Growth and Top Playerson November 24, 2020 at 9:42 pm
Europe oral antibiotics market accounted for $4,612.4 million in 2019 and will grow by 3.8% annually over 2020-2030 ...
- Hospital staff stress importance of antibiotic awarenesson November 24, 2020 at 6:23 pm
Tuesday is the last day of Antibiotic Awareness Week, highlighting the importance of appropriate antibiotic use, especially during a pandemic. Tristian O’Driscoll is the antimicrobial steward ...
- CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonason November 24, 2020 at 6:00 am
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant ...
- Longitude Prize launches AMR Voices: Stories from the frontlines of antibiotic resistance during Covid-19on November 23, 2020 at 4:02 pm
From the frontlines of the pandemic in the UK, US, South Africa and India, AMR Voices, shows how the real-life experience of antimicrobial resistance (AMR) collides with the realities of Covid-19.
- CF Foundation Awards up to $3.75M to Matinas BioPharma to Develop Oral Version of Antibiotic for NTM Infectionson November 20, 2020 at 6:00 am
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatmentBETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation ...
- FT Health: Future of Antibioticson November 18, 2020 at 6:18 pm
The Room Where It Happened : A White House Memoir Hardcover – 23 Jun. 2020 by John Bolton (Author). As President Trump’s National Security Advisor, John Bolton spent many of his 453 days in the room ...
- Antibiotic resistance: a matter of timeon November 17, 2020 at 9:00 pm
Now, even cuts have fatal consequences. Has the clock really been ticking towards a post-antibiotic future, where drug-resistant infections kill 10m people a year? Where chemotherapy is unsafe?
- The Antibiotic Gambleon November 11, 2020 at 10:01 pm
Evan Loh, chief executive of the U.S. firm Paratek Pharmaceuticals, leads a team that is striving to secure the future of a new antibiotic. Credit: Hannah Yoon for Nature Bringing a new antibiotic ...
- Clinicians who prescribe unnecessary antibiotics fuel future antibiotic useon November 9, 2020 at 1:04 pm
They set out to answer the question: Could an initial prescription from a high-prescribing physician drive future antibiotic-seeking behavior among patients? It does, the analysis showed ...
- Clinicians who prescribe unnecessary antibiotics fuel future antibiotic useon November 9, 2020 at 11:19 am
Receipt of antibiotics for acute respiratory infections makes it more likely that patients and their families will seek care and receive antibiotics for future respiratory viral infections.
via Bing News